Dr. Moskowitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
28 Manitoba Rd
Newton, MA 02468
Education & Training
University of WashingtonFellowship, Pediatric Pulmonology, 1997 - 2001- University of WashingtonResidency, Pediatrics, 1994 - 1997
Harvard Medical SchoolClass of 1994
Certifications & Licensure
MA State Medical License 2008 - 2025
NH State Medical License 2023 - 2025
AK State Medical License 2006 - 2010- American Board of Pediatrics Pediatric Pulmonology
Clinical Trials
- Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF) Start of enrollment: 2004 Mar 01
Publications & Presentations
PubMed
- 1080 citationsElexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del AllelePeter G. Middleton, Marcus A. Mall, Pavel Dřevínek, Larry C. Lands, Edward F. McKone
The New England Journal of Medicine. 2019-10-31 - 682 citationsEfficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double...Harry G.M. Heijerman, Edward F. McKone, Damian G. Downey, Eva Van Braeckel, Steven M. Rowe
Lancet. 2019-11-23 - 244 citationsCarbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle ControlSylvain Meylan, Caroline B. M. Porter, Jason H. Yang, Peter Belenky, Arnaud Gutierrez
Cell Chemical Biology. 2017-02-16
Press Mentions
Characterization of Pseudomonas Aeruginosa from Subjects with Diffuse PanbronchiolitisOctober 8th, 2024
Grant Support
- Polymyxin-Resistant Pseudomonas In CF Lung InfectionNational Institute Of Allergy And Infectious Diseases2009–2010
- Polymyxin-Resistant Pseudomonas In CF Lung InfectionNational Institute Of Allergy And Infectious Diseases2007–2008
- Standard Versus Biofilm Susceptibility Testing In Cystic Fibrosis (CF)National Center For Research Resources2006
- Influence Of ENAC Regulators On CF Lung SeverityNational Heart, Lung, And Blood Institute2005–2006
- Genetics Of Cystic Fibrosis Lung SparingNational Center For Research Resources2004–2005
- Host-Pathogen Interactions In Cystic FibrosisNational Heart, Lung, And Blood Institute2001–2005
- Genetics Of Cystic Fibrosis Lung DiseaseNational Center For Research Resources2004
Industry Relationships
- Executive Medical Director, Vertex Pharmaceuticals2015 - 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
